论文信息 - Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial. - 字舞流文

Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial.

This phase 2 clinical trial in patients with high-risk sickle cell disease assesses the feasibility, safety, and 1-year event-free survival after myeloimmunoablative conditioning and familial haploidentical stem cell transplant.

M. Cairo | B. Grossman | Q. Shi | T. Moore | R. Weinberg | S. Shenoy | J. Talano

[1] J. Kurtzberg,et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. , 2017, Blood.

[2] K. Leung,et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. , 2016, Blood.

[3] M. Gladwin. Cardiovascular complications and risk of death in sickle-cell disease , 2016, The Lancet.

[4] M. Cairo,et al. Hematopoietic stem cell transplantation for sickle cell disease: state of the science , 2015, European journal of haematology.

[5] J. Jacobson,et al. T cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients , 2012, British journal of haematology.

[6] O. Platt,et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.